Latest News and Press Releases
Want to stay updated on the latest news?
-
CARMIEL, Israel, Feb. 23, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today that Yossi Maimon, the Company's Vice President and Chief Financial...
-
CARMIEL, Israel, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), announced today the closing of its previously announced underwritten public offering....
-
CARMIEL, Israel, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today the pricing of its previously announced underwritten public offering of...
-
CARMIEL, Israel, Feb. 15, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX) announced today that it intends, subject to market conditions, to offer and sell shares of...
-
CARMIEL, Israel, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE AMEX:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 8th...
-
CARMIEL, Israel, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 8th...
-
CARMIEL, Israel, Dec. 13, 2011 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive...